MoonLake Immunotherapeutics (MLTX) Debt Ratio (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Debt Ratio of 0.25 for Q1 2026, up 73.16% year-over-year from 0.14 in Q1 2025, and up 41.66% quarter-over-quarter from 0.17 in Q4 2025.
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Debt Ratio (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.25 for Q1 2026.
- In Q1 2026, Debt Ratio rose 73.16% year-over-year to 0.25; the TTM figure through Mar 2026 stood at 0.25 (up 73.16% YoY), while the FY2025 annual figure was 0.17, changed N/A from the prior year.
- Debt Ratio for Q1 2026 stood at 0.25, up from 0.17 in the prior quarter.
- The five-year high for Debt Ratio was 0.25 in Q1 2026, with the low at 0.14 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | MoonLake Immunotherapeutics | 1.11 Bn | 572.81 Mn | - | 0.17 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.17 |
| Mar 31, 2026 | 0.25 |
| Dec 31, 2025 | 0.17 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | 0.16 |
| Mar 31, 2025 | 0.14 |
| Mar 31, 2022 | 0.00 |
| Dec 31, 2021 | 3.10 |
| Dec 31, 2020 | 0.00 |